portmanteau inhibitor portmanteau inhibitor a portmanteau inhibitor is a drug that is a combination of two drug molecules, each of which is itself a type of inhibitor. the term was coined in 2007 by university of minnesota researchers who designed and synthesized a combination hiv reverse transcriptase inhibitor and an integrase inhibitor, and was further used in 2011 by a team of researchers combining an integrase inhibitor with a ccr5 entry inhibitor. footnotes "u of m researchers announce advance in treatment of hiv". 25 july 2007. retrieved 25 july 2007. "researchers discover new method to combat hiv". 25 july 2007. retrieved 25 july 2007. zhengqiang wang; eric m. bennett; daniel j. wilson; christine salomon; robert vince (2007). "rationally designed dual inhibitors of hiv reverse transcriptase and integrase". journal of medicinal chemistry. 50 (15): 3416–3419. citeseerx 10.1.1.535.8472. doi:10.1021/jm070512p. pmid 17608468. bodiwala, h. s.; sabde, s.; gupta, p.; mukherjee, r.; kumar, r.; garg, p.; bhutani, k. k.; mitra, d.; singh, i. p. (2011). "design and synthesis of caffeoyl-anilides as portmanteau inhibitors of hiv-1 integrase and ccr5". bioorganic & medicinal chemistry. 19 (3): 1256–63. doi:10.1016/j.bmc.2010.12.031. pmid 21227704. antiviral drugs: antiretroviral drugs used against hiv (primarily j05)capsid inhibitors lenacapavir (len) entry/fusion inhibitors (discovery and development) gp41 (enfuvirtide (enf, t-20))◊ ccr5 (maraviroc (mvc) vicriviroc†, cenicriviroc†, leronlimab†) cd4 (ibalizumab (iba), semzuvolimab§) gp120 (fostemsavir (ftr)) integrase inhibitors(integrase strand transfer inhibitors (insti)) bictegravir (bic) cabotegravir (cab) dolutegravir (dtg)# elvitegravir (evg) raltegravir (ral)# bi 224436† mk-2048† maturation inhibitors bevirimat† bms-955176§ fipravirimat§ protease inhibitors (pi)(discovery and development)1st generation amprenavir (apv)‡ fosamprenavir (fpv) indinavir (idv)◊ lopinavir (lpv) nelfinavir (nfv)◊ ritonavir (rtv)# saquinavir (sqv)◊ 2nd generation atazanavir (atv)°# darunavir (drv)°# tipranavir (tpv)◊ tmc-310911§ reverse-transcriptase inhibitors (rtis)nucleoside and nucleotide (nrti) nucleoside analogues/nrtis: abacavir (abc)# didanosine (ddi)◊ emtricitabine (ftc) lamivudine (3tc)# stavudine (d4t)◊ zalcitabine (ddc)‡ zidovudine (azt, zdv)# amdoxovir† apricitabine† censavudine† elvucitabine† islatravir (efda, isl)§ racivir† stampidine† nucleotide analogues/ntrtis: tenofovir disoproxil (tdf)# tenofovir alafenamide (taf) non-nucleoside (nnrti)(discovery and development)1st generation efavirenz (efv)# nevirapine (nvp)# delavirdine (dlv)‡ 2nd generation diarylpyrimidines etravirine (etr) rilpivirine (rpv) doravirine (dor) combined formulations abacavir/lamivudine# abacavir/dolutegravir/lamivudine° abacavir/lamivudine/zidovudine atazanavir/cobicistat bictegravir/emtricitabine/tenofovir alafenamide° cabotegravir/rilpivirine darunavir/cobicistat darunavir/cobicistat/emtricitabine/tenofovir alafenamide° dolutegravir/emtricitabine/tenofovir alafenamide dolutegravir/lamivudine° dolutegravir/lamivudine/tenofovir alafenamide° dolutegravir/lamivudine/tenofovir disoproxil°# dolutegravir/rilpivirine doravirine/lamivudine/tenofovir disoproxil efavirenz/emtricitabine/tenofovir disoproxil# efavirenz/lamivudine/tenofovir disoproxil# elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil emtricitabine/tenofovir alafenamide emtricitabine/rilpivirine/tenofovir alafenamide emtricitabine/rilpivirine/tenofovir disoproxil emtricitabine/tenofovir disoproxil# lamivudine/nevirapine/stavudine lamivudine/nevirapine/zidovudine lamivudine/raltegravir lamivudine/tenofovir disoproxil# lamivudine/zidovudine# lopinavir/ritonavir# pharmacokinetic boosters cobicistat (c) ritonavir (r)# experimental agentsuncoating inhibitors trim5alpha (gene) transcription inhibitors tat antagonists translation inhibitors trichosanthin bnabs elipovimab other abzyme bit225† calanolide a ceragenin cyanovirin-n diarylpyrimidines epigallocatechin gallate (egcg) foscarnet fosdevirine† griffithsin hydroxycarbamide kp-1461† miltefosine portmanteau inhibitors scytovirin seliciclib† synergistic enhancers tre recombinase zinc finger protein transcription factor failed agents aplaviroc atevirdine brecanavir capravirine dexelvucitabine droxinavir lasinavir emivirine lersivirine lodenosine loviride mozenavir palinavir telinavir #who-em ‡withdrawn from market clinical trials: †phase iii §never to phase iii °dhhs recommended initial regimen options. ◊formerly or rarely used agent. this article is issued from wikipedia. the text is licensed under creative commons - attribution - sharealike. additional terms may apply for the media files.